title: [Intestinal inflammatory diseases].
abstract: There was no real therapeutic advances in inflammatory bowel diseases last year. In addition to infliximab, new anti-TNF-alpha agents will soon become available.
authors.affiliation: Service de gastro-entérologie et hépatologie, CHUV, 1011 Lausanne.
authors.forename: Christian
authors.initials: C
authors.lastname: Felley
authors.forename: Christian
authors.initials: C
authors.lastname: Mottet
authors.forename: Jurg
authors.initials: J
authors.lastname: Hess
authors.forename: Pascal
authors.initials: P
authors.lastname: Juillerat
authors.forename: Jean
authors.initials: J
authors.lastname: Guyot
authors.forename: Joakim
authors.initials: J
authors.lastname: Delarive
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
mesh_terms: D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000209:etiology / Q000517:prevention & control; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans